Overview

Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy

Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To assess the Efficacy and Safety of Dengzhanxixin Injection in Patients With Acute Ischemic Stroke Receiving Reperfusion Therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Tiantan Hospital